Market News

Metagenomi, Inc. Class Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Metagenomi, Inc. – Metagenomi (NASDAQ:MGX)

Upcoming Lead Plaintiff Deadline is November 25, 2024

NEW YORK, Oct. 30, 2024 /PRNewswire/ — Wolf Haldenstein Adler Freeman & Herz LLP (“Wolf Haldenstein“) announces that a federal securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of persons and entities that purchased or otherwise acquired Metagenomi, Inc. (“Metagenomi” or the “Company”) MGX securities between February 6, 2024 and September 26, 2024, inclusive (the “Class Period”).

CLICK HERE TO PROVIDE CONTACT INFORMATION AND JOIN THE CASE

All investors who purchased shares and incurred losses are advised to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action or join the case on our website, www.whafh.com.

If you have incurred losses, you may, no later than November 25, 2024, request that the Court appoint you as the lead plaintiff of the proposed class. Please contact Wolf Haldenstein to learn more about your rights.

On or around February 9, 2024, Metagenomi conducted its initial public offering (“IPO”) of 6.25 million shares of common stock priced at $15.00 per share. 

Then, on May 1, 2024, Metagenomi announced that it and Moderna, Inc. had “mutually agreed to terminate their collaboration on primary hyperoxaluria type 1 (PH1),” and that “the rights to develop the PH1 pro-gram, as well as all other rights granted under the collaboration, will be returned [to
Metagenomi] as part of the termination.”

On this news, Metagenomi’s stock price fell $0.87 per share, or 12.36%, to close at $6.17 per share on May 2, 2024.

See also  SBC Medical Group (Nasdaq: SBC) CEO: "If We Become No. 1 In Asia, I Believe We Will Become No. 1 In The World" - SBC Medical Group Holding (NASDAQ:SBC)

Wolf Haldenstein has experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas, and offices in New York, Chicago, Nashville and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735 or via e-mail at classmember@whafh.com.

Contact:

Wolf Haldenstein Adler Freeman & Herz LLP
Gregory Stone, Director of Case and Financial Analysis
Email: gstone@whafh.com or classmember@whafh.com
Tel: (800) 575-0735 or (212) 545-4774

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/metagenomi-inc-class-action-alert-wolf-haldenstein-adler-freeman–herz-llp-reminds-investors-that-a-securities-class-action-lawsuit-has-been-filed-in-the-united-states-district-court-for-the-northern-district-of-california-aga-302292195.html

SOURCE Wolf Haldenstein Adler Freeman & Herz LLP

Market News and Data brought to you by Benzinga APIs